RESPONSE BIOMEDICAL CORP - FORM 10-K/A - May 16, 2012

Attached files

file filename
EX-31.2 - EXHIBIT 31.2 - RESPONSE BIOMEDICAL CORPex31-2.htm
EX-31.1 - EXHIBIT 31.1 - RESPONSE BIOMEDICAL CORPex31-1.htm
EX-10.31 - EXHIBIT 10.31 - RESPONSE BIOMEDICAL CORPex10-31.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/A
Amendment No. 2
(Mark One)
  x  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2011
Or
  o  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________________ to _______________________
Commission file number: 000-50571
RESPONSE BIOMEDICAL CORPORATION
(Exact name of registrant as specified in its charter)
 
Vancouver, British Columbia, Canada
98 -1042523
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
   
1781 - 75th Avenue W.
Vancouver, British Columbia, Canada
V6P 6P2
(Address of principal executive offices)
(Zip Code))
Registrant's telephone number, including area code: (604) 456-6010
Securities registered pursuant to Section 12(b) of the Act: NONE
Securities registered pursuant to Section 12(g) of the Act:
COMMON STOCK WITHOUT PAR VALUE
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes o   No x
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes o   No x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x   No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x   No o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. x
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer o
Accelerated filer o
Non-accelerated filer o
(Do not check if a smaller
reporting company)
Smaller reporting company x
Indicate by check mark if the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o   No x
The aggregate market value of the voting common stock held by non-affiliates of the Registrant (assuming officers, directors and 10% stockholders are affiliates), based on the last sale price for such stock on June 30, 2011: $14,136,998.  The Registrant has no non-voting common stock.
As of March 23, 2012, there were 129,078,166 shares of the Registrant's common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
 
The Registrant makes available free of charge on or through its website (http://www.responsebio.com) its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934.  The material is made available through the Registrant's website as soon as reasonably practicable after the material is electronically filed with or furnished to the U.S. Securities and Exchange Commission, or SEC.  All of the Registrant's filings may be read or copied at the SEC's Public Reference Room at 100 F Street, N.E., Room 1580, Washington D.C. 20549.  Information on the hours of operation of the SEC's Public Reference Room can be obtained by calling the SEC at 1-800-SEC-0330.  The SEC maintains a website (http://www.sec.gov) that contains reports and proxy and information statements of issuers that file electronically.
 
 
 
 
 
EXPLANATORY NOTE
 
     This Amendment No. 2 on Form 10-K/A (this “Amendment”) amends the Annual Report on Form 10-K (the “Original Annual Report”) for the year ended December 31, 2011, which was originally filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2012. We are filing this Amendment in response to a comment letter received from the SEC (the “Comment Letter”) in connection with its review of our application for confidential treatment for certain omitted portions of Exhibit 10.31. We have modified Part IV Item 15(b), “Exhibits” in this Amendment to reflect our revised request for confidential treatment for Exhibit 10.31. We are re-filing herewith Exhibit 10.31 omitting certain portions for which we have applied for confidential treatment.
 
      Except as described above, no attempt has been made in this Amendment to modify or update other disclosures presented in the Original Annual Report. This Amendment does not reflect events occurring after the filing of the Original Annual Report or modify or update those disclosures, including the exhibits to the Original Annual Report affected by subsequent events. Accordingly, this Amendment should be read in conjunction with our filings with the SEC subsequent to the filing of the Original Annual Report, including any amendments to those filings.
 
 
 
 
 
PART IV
 
ITEM 15.           Exhibits and Financial Statement Schedules.
 
 (b)          Exhibits: The following exhibits are filed as a part of this report:
 
All other financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.

Exhibit
Number
  
Exhibit Description
  
Incorporated by Reference
3.1
  
Certificate of Incorporation dated August 20, 1980
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20-F for the year ended December 31, 2004, as filed on May 2, 2005.
3.2
  
Company Act Name Change dated October 15, 1991
  
**
3.3
  
Articles of the Company dated April 10, 1997
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Registration Statement on Form 20-F filed on February 4, 2004.
4.1
  
Escrow Agreement dated July 29, 2004
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20-F for the year ended December 31, 2004, as filed on May 2, 2005.
10.1
  
Alexandria New Facility Lease Agreement dated April 24, 2007
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2008 as filed on March 31, 2009.
10.2
  
Alexandria – First Amendment to Lease Agreement dated May 18, 2007
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2008 as filed on March 31, 2009.
10.3
  
Creation Technologies Supply Agreement dated August 19, 2005
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Report on Form 6-K filed on April 2, 2008.
10.4
  
Roche License Agreement – NT-proBNP dated July 22, 2005*
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2008 as filed on March 31, 2009.
10.5
  
Roche License Agreement –Amendment 2 concluded  July 26, 2005 – dated June 24, 2008*
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2008 as filed on March 31, 2009.
10.6
  
Roche Sales and Supply Agreement dated June 25, 2008*
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2008 as filed on March 31, 2009.
10.7
  
Shionogi Supply Agreement dated May 12, 2006
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2008 as filed on March 31, 2009.
10.8
  
Shionogi Supply Agreement – Amendment 1 dated July 11,  2008
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2008 as filed on March 31, 2009.
10.9
  
3M Master Manufacturing and Supply Agreement dated November 30, 2006 (Redacted)*
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2008 as filed on March 31, 2009.
10.1
  
3M/Response Investment Agreement dated November 30, 2006
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Report on Form 6-K filed on December 19, 2006.
10.11#
  
Contract – S. Wayne Kay, Chief Executive Officer
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2008 as filed on March 31, 2009.
10.12#
  
Contract – D. Morris, Chief Operating Officer
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2008 as filed on March 31, 2009.
10.13#
  
Contract – L. Kaler, Vice President Finance and Administration
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2009 as filed on April 1, 2010.
 
 
 
 
 
10.14#
  
Contract – Paul Harris, Vice President, Research and Development
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2008 as filed on March 31, 2009.
10.15#
  
Short Term Incentive Plan dated March 18, 2008
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2008 as filed on March 31, 2009.
10.16#
  
2008 Stock Option Plan
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2008 as filed on March 31, 2009.
10.17
  
Irrevocable Commercial Letter of Credit dated May 1, 2007
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2008 as filed on March 31, 2009.
10.18#
  
Form of Indemnification Agreement between Response Biomedical Corp. and applicable officers
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2008 as filed on March 31, 2009.
10.19
  
Demand Operating Facility Agreement dated April 26, 2007 with Schedule A
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2009 as filed on April 1, 2010.
10.20#
  
1996 Stock Option Plan, as amended June 21, 2004
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20-F for the year ended December 31, 2004, as filed on May 2, 2005.
10.21#
  
2005 Stock Option Plan
  
Previously filed as an exhibit to, and incorporated herein by reference from our Report on Form 6-k filed on June 23, 2005.Previously filed as an exhibit to, and incorporated herein by reference from, our Report on Form 6-K filed on April 2, 2008.
10.22#
  
2005 Stock Option Plan, as amended June 22, 2006
  
Previously filed as an exhibit to, and incorporated herein by reference from our Report on Form 6-k filed on June 23, 2005.Previously filed as an exhibit to, and incorporated herein by reference from, our Report on Form 6-K filed on April 2, 2008.
10.23
  
Warrant Certificate – Othmar Iseli dated October 28, 2008
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2008 as filed on March 31, 2009.
10.24
  
Warrant Certificates – various – dated October 28, 2008
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2008 as filed on March 31, 2009.
10.25
  
Underwriting Agreement Public Offering dated May 7, 2009
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2009 as filed on April 1, 2010.
10.26
  
Executed Warrant Indenture dated May 21, 2009
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2009 as filed on April 1, 2010.
10.27
  
Form of Warrants
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2009 as filed on April 1, 2010.
10.28
  
Broker’s Warrant Certificate dated May 21, 2009
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2009 as filed on April 1, 2010.
10.29
  
Form of Subscription Agreement
  
Previously filed as an exhibit to, and incorporated herein by reference from, our Annual Report of Form 20F for the year ended December 31, 2009 as filed on April 1, 2010.
10.30
  
Subscription Agreement dated June 27, 2010
  
**
10.31
  
Distribution Agreement with O&D Biotech Co., Ltd. China dated February 21, 2011*
  
***
10.32
  
Note Purchase Agreement dated November 22, 2011
  
**
10.33
  
Standby Purchase Agreement dated November 28, 2011
  
**
10.34#
  
Consulting Agreement dated October 28, 2011, by and between the Company and Richard Canote
  
**
14
  
Company’s Code of Ethics
  
**
 
 
 
 
 
23.1
  
Consent of Independent Registered Public Accounting Firm
  
**
24
  
Power of Attorney (included on signature page)
  
**
31.1
  
CEO's Certification required by Rule 13A-14(a) of the Securities Exchange Act of 1934
  
***
31.2
  
CFO's Certification required by Rule 13A-14(a) of the Securities Exchange Act of 1934
  
***
32.1
  
CEO's Certification of periodic financial reports pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, U.S.C. Section 1350
  
**
32.2
  
CFO's Certification of periodic financial reports pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, U.S.C. Section 1350
  
**
 
# 
Management compensatory plan, contract or arrangement
*
Confidential portion of this exhibit has been omitted and filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.
**
Previously filed with our Annual Report on Form 10-K for the year ended December 31, 2011 as filed on March 29, 2012.
***
Filed herewith.
 
Copies of the exhibits filed with this Annual Report on Form 10-K or incorporated by reference herein do not accompany copies hereof for distribution to stockholders of the Registrant.  The Registrant will furnish a copy of any of such exhibits to any stockholder requesting the same for a nominal charge to cover duplicating costs.

 
 
 
 
SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned thereunto duly authorized.
 
Dated: May 16, 2012
Response Biomedical Corporation
  
       
 
By:
/s/ Dr. Peter A. Thompson
  
   
Dr. Peter A. Thompson
  
   
Acting Chief Executive Officer and
  
    Chairman of Board of Directors  
 
Dated: May 16, 2012
By:
/s/ Richard A. Canote
  
   
Richard A. Canote
  
   
Chief Financial Officer
  
 
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
Dated: May 16, 2012
By:
/s/ Dr. Peter A. Thompson
  
   
Dr. Peter A. Thompson
  
   
Acting Chief Executive Officer and
  
   
Chairman of Board of Directors
  
 
Dated: May 16, 2012
By:
/s/ *
  
   
Dr. Anthony F. Holler
  
   
Chief Financial Officer and Treasurer
  
       
 
Dated: May 16, 2012
By:
/s/ *
  
   
Dr. Joseph D. Keegan
  
   
Director
  
 
Dated: May 16, 2012
By:
/s/ *
  
   
Clinton H. Severson
  
   
Director
  
 
Dated: May 16, 2012
By:
/s/ *
  
   
Lewis J. Shuster
  
   
Director
  
 
Dated: May 16, 2012
By:
/s/ *
  
   
Dr. David Wang
  
   
Director
  
 
 
 
* By
/s/ Dr. Peter A. Thompson
    
       
Dr. Peter A. Thompson
    
     
Attorney-in-Fact
    
 

RESPONSE BIOMEDICAL CORP Reports